This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Sedative Effects of Low-Dose Risperidone in GAD Patients and Risk of Drug Interactions

Miloslav Kopecek, MD; Pavel Mohr, MD, PhD; and Tomas Novak, MD

Published: August 1, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Based on their results, Brawman-Mintzer et al.1 suggest that adjunctive risperidone at low doses may represent a useful tool in the management of symptomatic generalized anxiety disorder (GAD) patients. They found statistically significant improvements in core anxiety symptoms as demonstrated by greater reduction in Hamilton Rating Scale for Anxiety (HAM-A) total scores (p = .034) and HAM-A psychic anxiety factor scores (p = .047) compared with placebo. The authors also conclude that between-group differences in reported adverse events were not clinically significant.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 67

Quick Links: